Firma Noxxon Pharma, Autor bei PR-Web

NOXXON renforce son conseil consultatif scientifique pour le cancer du pancréas et y nomme des experts en oncologie de renommée mondiale

Posted on 8. February 20214. July 2021 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, biomarqueurs, cancer, chiorean, est, growth, honor, iri, les, noxxon, pancréas, patients, professeure, seufferlein, tgen

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société biopharmaceutique développant principalement des traitements contre le cancer en ciblant le microenvironnement tumoral (MET), annonce aujourd’hui la nomination de quatre grands experts en oncologie au sein de son Conseil Consultatif Scientifique […]

NOXXON appoints leading pancreatic cancer experts to scientific advisory board

Posted on 8. February 20214. July 2021 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, cancer, chiorean, docetaxel, gemcitabine, honor, iri, irinotecan, nox, noxxon, patients, saro, seufferlein, tgen, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of four leading pancreatic cancer experts to its Scientific Advisory Board (SAB). Led by the […]

NOXXON annonce une nouvelle augmentation de capital de 6,4 m€ via un placement privé pour soutenir la

Posted on 26. January 20214. July 2021 by Firma Noxxon Pharma Posted in General Tagged a12, cancer, cotation, déclarations, est, growth, les, m??, nox, noxxon, produits, prospectives, souscription, taux, une

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société biopharmaceutique développant principalement des traitements contre le cancer en ciblant le microenvironnement tumoral (MET), annonce aujourd’hui le succès de son augmentation de capital par émission de nouvelles actions ordinaires avec suppression […]

NOXXON announces capital increase of €6.4 million by private placement to further develop its business

Posted on 26. January 20214. July 2021 by Firma Noxxon Pharma Posted in General Tagged a12, brain, cancer, dividend, financial, market, new, nox, noxxon, report, shareholders, statements, supervisory, tumor, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the successful completion of its capital increase by issuing new ordinary shares with exclusion of pre-emptive subscription […]